Stage I Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Verified date | March 2024 |
Source | Case Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies the efficacy (activity), and tolerability of curcumin and cholecalciferol combination in treating patients with previously untreated stage 0-II chronic lymphocytic leukemia or small lymphocytic lymphoma. Curcumin and cholecalciferol may prevent or slow the growth of cancer cells.
Status | Completed |
Enrollment | 35 |
Est. completion date | December 13, 2018 |
Est. primary completion date | April 4, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have a diagnosis of CLL based on peripheral blood flow cytometry and/or bone marrow aspiration and biopsy OR diagnosis of SLL based on lymph node or bone marrow biopsy; patients with SLL need to have measurable disease - Performance status (Eastern Cooperative Oncology Group [ECOG]) 0-2 - Patients must have not received any prior treatment for CLL or SLL - Patients must be stage 0-II based on Rai staging system; must have no indication for treatment for SLL per NCI-WG criteria - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Hemoglobin >= 10 g/dL - Serum creatinine =< 2.0 g/dL or calculated creatinine clearance (CrCl) >= 60mL/min (Cockcroft-Gault method) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN) - Bilirubin < 2.0 x ULN, unless subject has Gilbert's disease - Calcium < 10.1 mg/dL (corrected to serum albumin) - Females will be either postmenopausal for at least 1 year or surgically sterile for at least 3 months OR females of child-bearing potential must have a negative pregnancy test at screening and agree to take appropriate precautions to avoid pregnancy (double barrier method of birth control or abstinence) from screening through 3 months after the last dose of treatment - Able to comprehend and willing to sign an Informed Consent Form (ICF) - Subjects must be off any steroids 7 days prior to the initiation of treatment - Subjects must be off any curcumin, tumeric, or vitamin D supplements for 14 days prior to the initiation of treatment - Subjects must be able to take oral medications Exclusion Criteria: - Presence of malignancy (other than the one treated in this study) which required systemic treatment within the past 3 years - Any indication to start treatment for CLL based on NCI-WG criteria - Prior therapy for CLL/SLL - Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with curcumin - Concurrent medical condition which may increase the risk of toxicity, including: - Hypercalcemia of any cause - Untreated hyperparathyroidism - Paget's disease of bone - Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements as judged by treating physician; subjects receiving antibiotics that are under control may be included in the study - Inability to take oral medications - Patients receiving other investigational agent - History of allergic reactions attributed to compounds of similar chemical or biologic composition to curcumin or vitamin D or other agents used in this study - Patients on therapeutic anticoagulation, with heparin (or low-molecular weight heparin), warfarin, or a direct thrombin inhibitor as the safety of concurrent administration of curcumin has not been established - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible |
Country | Name | City | State |
---|---|---|---|
United States | Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Paolo Caimi, MD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate Based on NCI-WG (for CLL) and Cheson Criteria (for SLL) | The point estimate of the overall response rate (biologic response rate + complete response [CR] + partial response [PR]) with 95% confidence intervals will be calculated using binomial distribution theory.
The time measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented and assessed |
Up to 2 years | |
Secondary | Time to First Cytotoxic Treatment (TFCT) | TFCT defined as the time from entry onto study until initiation of treatment with cytotoxic agents because of disease progression.
Kaplan-Meier method and Cox proportional hazard model will be used for the data analysis. |
Up to 2 years | |
Secondary | Percent of Participants With Progression Free Survival (PFS) | Percent of participants that reached 2-year survival without disease progression.
PFS is defined as the time from entry onto study until CLL/SLL progression or death from any cause. National Cancer Institute Working Group (NCI-WG) criteria is used for CLL participants and Cheson Criteria is used for SLL participants |
Up to 2 years | |
Secondary | Overall Survival (OS) | Number of participants still alive at 2 years after treatment discontinuation. | Up to 2 years | |
Secondary | Duration of Response | Time from achievement of partial response, complete response or biologic response to disease progression | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Terminated |
NCT00377104 -
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01441882 -
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00098670 -
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT00303966 -
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT01351896 -
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01024010 -
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT01789255 -
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT01361711 -
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00918723 -
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00003620 -
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT02309515 -
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
|
Phase 2 | |
Active, not recruiting |
NCT02213913 -
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT01269385 -
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT01649791 -
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
|
N/A |